MeiraGTx Earns $50M Milestone from Janssen Pharma Deal
Company Announcements

MeiraGTx Earns $50M Milestone from Janssen Pharma Deal

Meiragtx Holdings Plc (MGTX) has released an update.

MeiraGTx Holdings plc has reached a significant milestone by earning $50 million from Janssen Pharmaceuticals, as part of their December 2023 agreement for botaretigene sparoparvovec, a gene therapy treatment for X-linked retinitis pigmentosa. This achievement underscores the company’s progress and potential in the field of medical biotechnology, marking a notable moment for investors watching the innovative therapy’s journey towards commercial success.

For further insights into MGTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyMeiraGTx reports Q3 EPS (55c) vs (74c) last year
TheFlyMeiraGTx announecs five posters at ESGCT 2024 Annual Congress
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App